Fujifilm to introduce artificial intelligence initiative for United States market at RSNA 2017

Nov. 27, 2017

FUJIFILM Medical Systems U.S.A., a provider of enterprise imaging and medical informatics solutions, announced the expansion of Fujifilm’s artificial intelligence (AI) development initiative with entry in the U.S. market. Fujifilm’s AI development initiative will harness the power of AI to enhance its imaging and informatics healthcare Synapse portfolio which includes Synapse PACS, Synapse Cardiovascular, and Synapse VNA among other solutions. The initiative will be on display at booth #4111 in the South Hall of McCormick Place in Chicago at the Radiological Society of North America’s (RSNA).

The program will be based in Raleigh, North Carolina—the global development headquarters for Fujifilm’s Synapse portfolio in collaboration with FUJIFILM Corporation’s development team in Tokyo  that will provide a wide range of image recognition technologies. Fujifilm will partner with its strategic customers in the U.S. market, to draw upon clinical insights and expertise in the field to bridge AI applications to imaging informatics solutions.

In an increasingly complex healthcare environment with larger datasets, and rising demand for high quality care, AI will have the potential to change the practice of medicine. The AI revolution is underway and with its long history of innovation, Fujifilm is at the forefront of development to refine this disruptive technology for medical imaging and healthcare informatics.

RSNA has the full release